Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech
14th Nov 2006, 14:16 GMT
LOS ANGELES, CA (MARKET WIRE) Eugene Science, Inc. (OTCBB: EUSI), a developer and marketer of advanced nutraceutical products, today announced it has established a strategic distribution alliance with RexGene Biotech under which RexGene will manufacture and market several cholesterol-lowering nutracuetical products containing Eugene Science's patented CZ(TM) ingredient.
Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech related news:
- Eugene Science Signs Major Distribution Agreement With RexGene Biotech — ArriveNet : Press Releases
- AbioMed wins $16M Japanese distribution deal — bizjournals.com Health Care:Industry Regulation headlines
- Abiomed signs Japanese distribution deal — Latest news from Boston Business Journal
- For the record 14 November — ElectricNews.net
- Abiomed Announces 5-Year, $16+ mln Impella and AB5000 Distribution Agreement with Medix Japan — Distribution/ Logistics News from StratCenter.com
- BioTech Medics, Inc.: BioTech Medics Announces Pinksheets Quotation — Market Wire - Medical and Healthcare
- Amazon Biotech, Inc: Amazon Biotech Inc. Announces Union Bless Herbal Products' Application for Amendment to Approved Import Drug License to Include Amazon Biotech as Approved Supplier — Market Wire - Pharmaceuticals and Biotech
- Industrial Biotechnology Corp: Industrial Biotechnology Corporation Signs Manufacturing Distribution Letter of Intent and Cooperation Agreement With Tianjin Zhongao Group — Market Wire - Chemicals
- Abiomed, Medix Japan in Distribution Pact — Distribution/ Logistics News from StratCenter.com
- Investor Notice: KGS Announces Investigation on Behalf of Investors in Bodisen Biotech, Inc. — ArriveNet : Press Releases
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- GelStat Corporation: GelStat Announces the Retention of Accomplished Business Development and Marketing Firm U.S. Marketing